Sun Pharma’s $11.75 bn all‑cash purchase of Organon makes it a top‑three player in women’s health and a major biosimilar contender, but the deal hinges on a segment that is already falling. Organon’s Q1 results showed a 19% drop in women’s‑health sales and a 28% plunge in its flagship contraceptive implant, raising doubts about the debt‑financed deal’s cash‑flow assumptions.
Adani Infra (India) Ltd, the promoter‑owned infrastructure unit of the Adani Group, has amassed an orderbook exceeding ₹50,000 crore and is projected to generate around ₹10,000 crore in annual revenue. Acting as a project‑management consultant for Adani’s ports, roads, airports and power projects, it is now eyeing acquisitions to bring EPC capabilities in‑house, having already bought Punj Lloyd and taken a stake in PSP Projects.
Reliance Industries' FY26 annual report indicates new hires may have dropped by as many as 90,000 versus the prior year, signaling a shift toward AI‑driven productivity and upskilling. Despite the cut, total headcount rose to over 4.19 lakh, while its Jio Platforms arm saw a 21% workforce decline.